Brief: Nanobiotix And Lianbio Announce First Patient Enrolled In Asia In Phase 3 Nanoray-312 Trial Evaluating Nbtxr3 For Treatment Of Head And Neck Cancer

Nanobiotix SA

07/09/2022 21:21

Sept 7 (Reuters) - LianBio  LIAN.O :
    * NANOBIOTIX AND LIANBIO ANNOUNCE FIRST PATIENT ENROLLED IN
ASIA
IN PHASE 3 NANORAY-312 TRIAL EVALUATING NBTXR3 FOR TREATMENT OF
HEAD AND NECK CANCER

Source text for Eikon:  ID:nBw59169Ya 
Further company coverage:  LIAN.O 

 ((Reuters.Briefs@thomsonreuters.com;))